CureDuchenne Webinar with Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, to brief the Duchenne community about Avidity’s research in pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).  The Webinar will feature Debra Miller, founder and CEO, CureDuchenne and Arthur A. Levin, Ph.D., EVP of research and development, Avidity Biosciences.

Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.